We are searching data for your request:
The pharmaceutical company GlaxoSmithKline wants to make compensation payments for the controversial diabetes medicine "Avendia" according to an agency report.
(14.07.2010) According to a recent agency announcement, the English pharmaceutical manufacturer "GlaxoSmithKline" will make compensation payments of a total of 460 million euros to the plaintiffs due to the controversial diabetes medicine "Avandia". Avandia is suspected of possibly causing fatal heart disease. It is said that there were clinical indications two years ago that the active ingredient "Rosiglitazone" contained in Avendia could damage the heart.
A total of 10,000 lawsuits have been brought against the pharmaceutical giant in the United States alone. "GlaxoSmithKline" wants to settle the dispute with the millions. The agency "Bloomberg" reported on Tuesday that such an agreement had been reached. The agency appeals to "familiar persons". So far, there has been no official statement from the plaintiffs or the group. The rush announcement of a possible settlement came on the eve of the important decision by the FDA. A committee plans to make a recommendation to the FDA on Wednesday whether the drug Avandia needs to be withdrawn from the market. The group did not want to comment on this at the time of the report.
The lawsuits came after a clinical study showed that the medicine for diabetic patients can lead to serious heart problems. Since then, the drug has been controversial and has been heavily criticized on all sides. According to the New York Times, an internal US government report recommended that Avandia be withdrawn from the market immediately. In addition, according to the Times, the drug caused 304 deaths in the third quarter of 2009 alone. Two US senators accused the pharmaceutical company of having known about possible heart problems before 2007.
European drug authorities will certainly re-examine the drug. In Germany, the Federal Joint Committee recently took the drug along with similar drugs from the reimbursement of the statutory health insurance companies. It has not yet been confirmed whether the pharmaceutical company was also sued in Germany. (sb)
Diabetes is not a fate
Avandia diabetes drug suspected of having a heart attack
Image: Rainer Sturm / pixelio.de